Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, Digiovanna MP, Fasching P, Crown JP, Wuelfing P, Shao Z, Caremoli ER, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Book Volume: 380

Pages Range: 617-628

Journal Issue: 7

DOI: 10.1056/NEJMoa1814017

Abstract

BACKGROUND

Authors with CRIS profile

Involved external institutions

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP) United States (USA) (US) GBG Forschungs GmbH (German Breast Group) Germany (DE) Hospital Universitario La Paz Spain (ES) Roche China Ltd. China (CN) National Taiwan University Hospital (NTUH) / 國立台灣大學醫學院附設醫院 Taiwan (TW) HELIOS Kliniken Germany (DE) Genentech Inc. United States (USA) (US) F. Hoffmann-La Roche Ltd Switzerland (CH) Universitätsklinikum Heidelberg Germany (DE) Fudan University / 复旦大学 China (CN) Yale University United States (USA) (US) University of Montpellier / Université Montpellier France (FR) National Cancer Institute (NCI) United States (USA) (US) Azienda Ospedaliera Papa Giovanni XXIII Italy (IT) Institute of Cancer of São Paulo Brazil (BR) Ireland Cooperative Oncology Research Group (Icorg) Ireland (IE)

How to cite

APA:

Von Minckwitz, G., Huang, C.-S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M.,... Geyer, C.E. (2019). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine, 380(7), 617-628. https://dx.doi.org/10.1056/NEJMoa1814017

MLA:

Von Minckwitz, G., et al. "Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer." New England Journal of Medicine 380.7 (2019): 617-628.

BibTeX: Download